Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
EXELDERM vs LOTRIMIN AF
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Topical antimycotic that inhibits fungal squalene epoxidase, leading to accumulation of squalene and disruption of fungal cell wall synthesis.
Inhibits fungal cytochrome P450 14α-demethylase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
Tinea pedis,Tinea cruris,Tinea corporis,Tinea versicolor
Tinea pedis,Tinea cruris,Tinea corporis,Pityriasis versicolor,Cutaneous candidiasis
Apply a thin layer to affected skin twice daily (morning and evening).
Topical: Apply twice daily (morning and evening) to affected area for 2-4 weeks. Intravaginal: One 200 mg suppository vaginally at bedtime for 3 days, or one 500 mg vaginal tablet as a single dose.
Not applicable due to negligible systemic absorption; after topical application, half-life in skin is several hours.
Terminal elimination half-life of absorbed clotrimazole is approximately 3.5–4 hours, but this is clinically irrelevant due to negligible systemic absorption after topical application.
Minimal systemic absorption; when absorbed, primarily metabolized in the liver via oxidation and glucuronidation.
Minimal systemic absorption; primarily local metabolism.
Systemic absorption is minimal; any absorbed sulconazole is primarily metabolized in the liver and excreted in feces via bile; renal excretion of unchanged drug is negligible.
Less than 1% of topical clotrimazole is absorbed; absorbed drug is metabolized in the liver to inactive metabolites and excreted primarily in feces (approximately 69%) and urine (approximately 21%) via biliary and renal routes.
Not applicable; systemic levels are undetectable with topical use.
Approximately 90–95% bound to plasma proteins, primarily albumin.
Not applicable; negligible systemic absorption.
Vd is approximately 2.5 L/kg after intravenous administration (data for systemic formulation); after topical application, systemic absorption is negligible (<1%), so Vd is not clinically meaningful.
Topical: negligible systemic bioavailability (<1%) due to poor percutaneous absorption.
Topical: Systemic bioavailability is <1% after application to intact skin; vaginal tablet: approximately 3–10% absorbed systemically.
No dosage adjustment required for renal impairment.
No dosage adjustment required for renal impairment.
No dosage adjustment required for hepatic impairment.
No dosage adjustment required for hepatic impairment.
Safety and efficacy in pediatric patients below 12 years have not been established; see prescribing information for age-specific recommendations.
Children ≥2 years: Same as adult dosing for topical application. Children <2 years: Not recommended without physician consultation.
No specific geriatric dose adjustments; use caution due to higher risk of adverse effects from prolonged use.
No specific dose adjustment; use same adult dosing with consideration of renal/hepatic function and potential drug interactions.
None.
None
Avoid contact with eyes, nose, mouth, or other mucous membranes. Discontinue if irritation or sensitization occurs. Not for oral or ophthalmic use. Use in children under 12 years not established.
For external use only,Avoid contact with eyes,Discontinue if irritation occurs,Not for vaginal or oral use
Known hypersensitivity to sulconazole or any component of the formulation.
Hypersensitivity to clotrimazole or any component
None known.
No clinically significant food interactions for topical clotrimazole.
Category B: No teratogenic effects in animal studies; no adequate human studies in first trimester. Avoid use in first trimester unless clearly needed.
Clotrimazole (Lotrimin AF) is category B. No evidence of teratogenicity in animal studies. Limited human data from topical use in first trimester show no increased risk of major malformations. Systemic absorption from topical application is minimal (<0.5%), making fetal exposure negligible. No known fetal risks from topical use in any trimester.
Not known if excreted in breast milk. Caution in nursing mothers; limited data. M/P ratio not available.
Topical clotrimazole is considered compatible with breastfeeding. Systemic absorption is minimal, and any excreted amounts in breast milk are negligible. M/P ratio is not available due to minimal absorption. Avoid application to breast area to prevent infant oral contact.
No dose adjustment required for topical use; insufficient data for systemic absorption changes.
No dose adjustment required for topical clotrimazole during pregnancy. Pharmacokinetics are not significantly altered as systemic absorption is minimal. Use standard dosing for indication (e.g., 1% cream twice daily for 2-4 weeks for dermatophytosis).
Apply sparingly to affected area; avoid use on mucous membranes or intertriginous areas. Discontinue if irritation occurs. Not recommended for use under occlusive dressings.
Lotrimin AF (clotrimazole) is a topical antifungal used for dermatophyte and yeast infections. For tinea pedis, apply twice daily for 4 weeks; shorter courses may lead to recurrence. Do not use in or near eyes. Avoid occlusive dressings unless directed.
Use only on the skin as directed; avoid contact with eyes, mouth, or open wounds.,Wash hands before and after applying unless treating hands.,Do not cover the treated area with bandages or wrappings unless directed by a doctor.,Stop use and consult doctor if condition worsens or does not improve within 2 weeks.,Inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding.
Apply a thin layer to affected skin twice daily, morning and evening.,Wash hands before and after application unless treating hands.,Continue use for the full prescribed duration even if symptoms improve.,Avoid contact with eyes, mouth, or open wounds.,Do not cover treated area with bandages or plastic unless instructed.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about EXELDERM vs LOTRIMIN AF, answered by our medical review team.
EXELDERM is a Topical Antifungal that works by Topical antimycotic that inhibits fungal squalene epoxidase, leading to accumulation of squalene and disruption of fungal cell wall synthesis.. LOTRIMIN AF is a Topical Antifungal that works by Inhibits fungal cytochrome P450 14α-demethylase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between EXELDERM and LOTRIMIN AF depend on the specific clinical indication. These are both Topical Antifungal agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of EXELDERM is: Apply a thin layer to affected skin twice daily (morning and evening).. The standard adult dose of LOTRIMIN AF is: Topical: Apply twice daily (morning and evening) to affected area for 2-4 weeks. Intravaginal: One 200 mg suppository vaginally at bedtime for 3 days, or one 500 mg vaginal tablet as a single dose.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between EXELDERM and LOTRIMIN AF in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. EXELDERM is classified as Category C. Category B: No teratogenic effects in animal studies; no adequate human studies in first trimester. Avoid use in first trimester unless clearly needed.. LOTRIMIN AF is classified as Category C. Clotrimazole (Lotrimin AF) is category B. No evidence of teratogenicity in animal studies. Limited human data from topical use in first trimester show no increased risk of major ma. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.